Burlingame, Calif.-based Inflammatix develops a molecular diagnostic designed to read the patient’s immune system to deliver rapid results, with an initial focus on acute infection and sepsis. Its HostDx tests combine proprietary biomarkers and advanced machine learning. The company was included on Medical Design & Outsourcing’s list of 20 startups you need to know.
Tests developed by Inflammatix can identify the presence and type of infection and the risk of severe disease to enable more informed decisions by physicians. The tests are run on the company’s sample-to-answer, cartridge-based, point-of-care Myrna test system designed to deliver results in under 30 minutes.
Funds raised in the Series D are earmarked to support regulatory clearance and global commercialization of the Myrna system, as well as the InSep acute infection and sepsis test. Money will also support the development of Inflammatix’s pipeline of diagnostics, including the ViraBac EZ acute infection test run from a fingerstick.
D1 Capital Partners led the round, while existing investors Northpond Ventures, Khosla Ventures, Think.Health and OSF Healthcare Ventures participated, too.
“We are thrilled to welcome D1 Capital Partners to our strong investor syndicate, and look forward to bringing host response diagnostics to market,” Inflammatix CEO and co-founder Dr. Tim Sweeney said in the release. “By quickly providing actionable information about disease, Inflammatix expects to equip physicians to make better clinical decisions that benefit both patients and healthcare systems.”